Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
131.7 USD | -0.06% | +6.59% | +20.87% |
03:02pm | Merck: new indication approved for Keytruda in Europe | CF |
01:45pm | Merck Says Keytruda Plus Chemotherapy as Neoadjuvant Treatment Receives Approval From European Commission | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.87% | 334B | |
+35.16% | 701B | |
+26.24% | 571B | |
+1.12% | 381B | |
+17.09% | 319B | |
+1.00% | 210B | |
+2.82% | 210B | |
-6.18% | 201B | |
-3.14% | 157B | |
-0.59% | 153B |
- Stock
- Equities
- Stock Merck & Co., Inc. - Nyse
- News Merck & Co., Inc.
- Merck & Co.'s Keytruda Fails To Extend Survival In Liver, Prostate Cancer Studies